GSK Reports the Acceptance of the Regulatory Application for Arexvy to Prevent Respiratory Syncytial Virus (RSV) Related Diseases
Shots:
- The MHLW accepts GSK's Arexvy regulatory application for review to extend the indication for the prevention of RSV disease in adults aged 50-59yrs.
- The submission is supported by the positive results of the P-III study evaluating the immune response & safety of RSV vaccine in 2 cohorts (n=570; aged: 50 to 59yrs. & 60 & older). The 1EP of the study includes RSV-A and RSV-B neutralization titers of both groups
- RSV vaccine comprises recombinant glycoprotein F (RSVPreF3) stabilized in the prefusion conformation along with GSK's exclusive AS01E adjuvant. The MHLW has authorized GSK's RSV vaccine for 60 yrs. & older for RSV illness
Ref: GSK | Image: GSK
Related News:- GSK’s Arexvy Receives EC’s Approval for the Prevention of Lower Respiratory Tract Disease in Individuals Aged ≥60 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
